Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer: A southwest oncology group study

D. D. Von Hoff, S. Green, E. A. Surwit, E. V. Hannigan, David S Alberts

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.

Original languageEnglish (US)
Pages (from-to)433-435
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number5
StatePublished - 1990
Externally publishedYes

Fingerprint

fludarabine phosphate
Uterine Cervical Neoplasms
Drug Therapy
Leukopenia
Proxy
Anemia
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer : A southwest oncology group study. / Von Hoff, D. D.; Green, S.; Surwit, E. A.; Hannigan, E. V.; Alberts, David S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 5, 1990, p. 433-435.

Research output: Contribution to journalArticle

@article{810c517a4a6242d8b34beea18ee11336,
title = "Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer: A southwest oncology group study",
abstract = "Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.",
author = "{Von Hoff}, {D. D.} and S. Green and Surwit, {E. A.} and Hannigan, {E. V.} and Alberts, {David S}",
year = "1990",
language = "English (US)",
volume = "13",
pages = "433--435",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer

T2 - A southwest oncology group study

AU - Von Hoff, D. D.

AU - Green, S.

AU - Surwit, E. A.

AU - Hannigan, E. V.

AU - Alberts, David S

PY - 1990

Y1 - 1990

N2 - Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.

AB - Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025131902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025131902&partnerID=8YFLogxK

M3 - Article

C2 - 1699401

AN - SCOPUS:0025131902

VL - 13

SP - 433

EP - 435

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -